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Summary
Family ZMK is a large Irish kindred that segregates pro-
gressive sensorineural hearing loss and retinitis pigmen-
tosa. The symptoms in the family are almost identical
to those observed in Usher syndrome type III. Unlike
that in Usher syndrome type III, the inheritance pattern
in this family is compatible with dominant, X-linked
dominant, or maternal inheritance. Prior linkage studies
had resulted in exclusion of most candidate loci and
190% of the genome. A tentative location for a causative
nuclear gene had been established on 9q; however, it is
notable that no markers were found at zero recombi-
nation with respect to the disease gene. The marked
variability in symptoms, together with the observation
of subclinical muscle abnormalities in a single muscle
biopsy, stimulated sequencing of the entire mtDNA in
affected and unaffected individuals. This revealed a
number of previously reported polymorphisms and/or
silent substitutions. However, a CrA transversion at po-
sition 12258 in the gene encoding the second mito-
chondrial serine tRNA, MTTS2, was heteroplasmic and
was found in family members only. This sequence
change was not present in 270 normal individuals from
the same ethnic background. The consensus C at this
position is highly conserved and is present in species as
divergent from Homo sapiens as vulture and platy-
pus. The mutation probably disrupts the amino
acid–acceptor stem of the tRNA molecule, affecting ami-
noacylation of the tRNA and thereby reducing the ef-
ficiency and accuracy of mitochondrial translation. In
summary, the data presented provide substantial evi-
dence that the C12258A mtDNA mutation is causative
of the disease phenotype in family ZMK.
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Introduction
Retinitis pigmentosa (RP) describes a genetically and
clinically heterogeneous group of disorders that are char-
acterized by gradual degeneration of photoreceptor cells,
often to the point where the patient is legally blind.
Common clinical features include a progressive loss of
night vision, leading to night blindness; peripheral-vi-
sual-field loss; abnormalities present on electroretino-
graphy; tunnel vision; optic-disk pallor; attenuation of
the retinal blood vessels; intraretinal pigment deposition;
and progressive visual handicap (Humphries et al. 1990,
1992; Wright 1992; Dryja and Li 1995; Kenna et al.
1997). RP can present either alone or as a syndromic
disorder. A syndrome incorporating both RP and various
degrees of sensorineural hearing loss was first described
by Charles Usher in 1914 (Usher 1914). Usher syndrome
is inherited in an autosomal recessive fashion, is genet-
ically and clinically heterogeneous, and has been divided
into three major categories based on (a) whether the
hearing loss is congenital or progressive, (b) presence or
absence of vestibular involvement, (c) severity of symp-
toms, and (d) age at onset (Kimberling et al. 1995).
Usher syndrome type I is characterized by profound con-
genital deafness, absent vestibular responses, and onset
of RP by age 10 years (Kimberling et al. 1995). Loci for
Usher syndrome type I have been localized to chromo-
somes 14q (USH1A [MIM 276900]; Kaplan et al. 1992),
11q (USH1B [MIM 276903]; Smith et al. 1992), 11p
(USH1C [MIM 276904]; Kimberling et al. 1992), 10q
(USH1D [MIM 601067]; Wayne et al. 1996), and 21q21
(USH1E [MIM 602097]; Chaib et al. 1997). Usher syn-
drome type 1B on 11q has been shown to be caused by
mutations in the myosin VIIA (MYO7A) gene (Weil et
al. 1995). Patients with Usher syndrome type II have
normal vestibular responses, onset of RP by the late
teens, and moderate to severe congenital deafness (Kim-
berling et al. 1995). Usher syndrome type II has been
linked to chromosomes 1q41 (USH2A [MIM 276901];
Kimberling et al. 1990) and 5q (USH2B [MIM 276905];
W. J. Kimberling, personal communication). Mutations
in USH2A have been found in the USH2A gene on 1q41
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(Eudy et al. 1998). Usher syndrome type III is charac-
terized by progressive onset of hearing loss and RP at
puberty or later and is prevalent in Finland (Karjalainen
et al. 1989); it has been localized to chromosome 3q
([MIM 276902] Sankila et al. 1995; Joensuu et al. 1996).
With the exception of myosin VIIA and USH2A, the
genes causing the remaining forms of Usher syndrome
remain to be identified.
Family ZMK, previously referred to as “ZMK-92”
(Kumar-Singh et al. 1993a, 1993b) and “TCD ZMK-
92” (Kenna et al. 1997) is an Irish kindred that segre-
gates progressive sensorineural hearing loss and RP. Al-
though the pattern of symptoms observed strongly re-
sembles that noted in Usher syndrome type III (Kenna
et al. 1997), family ZMK is unique in that the pattern
of inheritance is compatible with autosomal dominant,
X-linked dominant, and maternal transmission of the
disease locus (fig. 1). Extensive linkage analysis had ex-
cluded the majority of loci shown to be involved in var-
ious forms of RP, Usher syndrome, and some forms of
hearing loss and had resulted in the identification of a
putative linkage on the q terminal region of chromosome
9 (Kumar-Singh et al. 1993a, 1993b; Kenna et al. 1997).
LOD scores obtained on 9q marginally exceeded the
3.00 threshold of significance, with markers D9S118,
D9S121, and ASS (Kenna et al. 1997). However, the
putative disease locus could not be clearly defined, owing
to both a lack of mapped markers in this region of the
genome at the time and the fact that all three critical
markers were unmapped with respect to markers on the
Ge´ne´thon map (Gyapay et al. 1994). We have since
mapped the critical markers and have used this map to
perform extensive multipoint analyses extending over
the entire 9q region. In addition, the clinical status of
one family member has altered from unaffected to af-
fected. Results frommultipoint analysis and haplotyping
indicate that the disease gene in ZMK is now excluded
from this region of 9q. Additionally, extensive linkage
studies with this family have resulted in exclusion of
190% of the human nuclear genome. The possibility of
a large-scale chromosomal abnormality was also ruled
out by high-resolution karyotyping (Kenna et al. 1997).
Given extensive exclusion of the nuclear genome, a wide
variation in disease symptoms experienced by family
members, and abnormal findings from a single muscle
biopsy, it was decided to screen all 16,569 bp of the
mitochondrial genome, for mutations in affected mem-
bers of this kindred (Kenna et al. 1997). We present
evidence that a novel CrA transversion at position
12258 in the second mitochondrial serine tRNA gene
(MTTS2) is responsible for the progressive hearing loss
and RP observed in members of this family.
Patients and Methods
Patients
The assessment, diagnosis, and clinical attributes of
the family have been described elsewhere (Kumar-Singh
et al. 1993a, 1993b; Kenna et al. 1997). Blood samples
were obtained from 29 family members, who were clin-
ically assessed, and from 5 spouses of affected persons.
Informed consent was obtained from all persons who
participated in this study. DNA was extracted from
whole blood, according to standard methods. One in-
dividual underwent a quadriceps femoris muscle biopsy.
One half of this sample was used for electronmicroscopy
as reported elsewhere (Kenna et al. 1997), whereas DNA
from the other half was extracted as follows. Muscle
tissue was ground, in liquid nitrogen, in a mortar and
pestle until reduced to fine powder. The powder was
transferred to a tissue homogenizer, with 10 ml of di-
gestion buffer (100 mMNaCl, 10 mM Tris-HCl pH 8.0,
25 mM EDTA pH 8.0, 0.5% SDS, 0.1 mg of proteinase
K/ml [Boehringer Mannheim])/100–200 mg of tissue.
After homogenization, the sample was shaken overnight
at 37C. Three phenol extractions were performed, and
the sample was precipitated with 1/10 vol of 7.5 M
ammonium acetate and 2 vol of 95% ethanol chilled to
20C. The DNA was spun down at 1,200 g and was
washed twice with 70% ethanol. The pellet was air-dried
and resuspended in sterile dH2O.
Controls
The 270 control DNAs screened for the 12258 mu-
tation were obtained from a panel of unaffected indi-
viduals (provided by Dr. L. Mynett-Johnson) from the
same ethnic background as the ZMK family.
Linkage Studies
Primer sequences for microsatellite amplification were
obtained from the 1994 and 1996 Ge´ne´thon maps (Gya-
pay et al. 1994; Dib et al. 1996) and from Genome
Database. Markers were amplified by PCR with the in-
corporation of a[32P]-dATP or [32P]-dCTP label and then
were electrophoresed on 8% denaturing acrylamide gels.
Microsatellite data were prepared for analysis using the
Linksys version 4.11 data-management package (Att-
wood and Bryant 1988). Two-point linkage analysis was
performed by LIPED. Files for multipoint analysis were
generated by LINKSYS and MAKEPED. Multipoint
analyses were performed by LINKMAP from the FAST-
LINK package, version 3.0p (Cottingham et al. 1993;
Scha¨ffer et al. 1994). The frequency of the disease phe-
notype was set at .0001, whereas the frequency of the
normal phenotype was set at .9999. One-hundred-per-
cent penetrance was assumed, although some analyses
Figure 1 Family ZMK. Individuals denoted by an asterisk (*) have been clinically assessed in detail and have donated DNA samples. The individual denoted by a question mark (?), V-18, is
the affected granddaughter of an apparently unaffected individual (III-5). Generation numbers are given on the far left side, and numbers denoting individuals are given below the pedigree symbols.
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were completed by use of affected family members only.
Frequencies of marker alleles were assumed to be equal.
Multipoint analyses were performed under sex-specific
conditions. Since there is no confirmed affected-male-to-
offspring transmission in this pedigree, it was considered
important to take the greater female recombination rates
into account. Multipoint analyses were performed by
use of marker distances obtained from the LDB maps
(Collins et al. 1996a), except for chromosome 9, for
which the marker distances were obtained from our own
map (fig. 2). The chromosome 9 map was generated by
CRI-MAP, version 2.4 (Lander and Green 1987). Ge-
notype data used to build the map were, in the case of
markers D9S121 and D9S118, generated, by us, from a
subset of the CEPH families. The remaining genotype
data were downloaded from the CEPH database (Fon-
dation Jean Dausset–CEPH), were converted to CRI-
MAP format by MAP (Collins et al. 1996b), and were
combined with our own data by the CRI-MAP merge
option. Haplotypes were constructed by hand, from mi-
crosatellite data.
Mitochondrial Screening
DNA samples from four ZMK family members were
chosen to screen the entire mitochondrial sequence.
These family members included two severely affected
individuals (IV-22 and V-14), a member of the family
who was deemed to be unaffected (IV-18), and an un-
related control (IV-23, spouse of IV-22). The DNA sam-
ple from individual IV-22 was extracted from a muscle-
biopsy sample, since heteroplasmic mtDNA mutations
are occasionally undetectable in blood samples. The
other DNA samples were derived from blood. Mito-
chondrial primers were designed from the consensus
Cambridge mtDNA sequence (Anderson et al. 1981;
GenBank J01415), which was downloaded from MI-
TOMAP v3.0 (Wallace et al. 1995; Kogelnik et al.
1996), and were synthesized by VHBio and Genosys.
The mitochondrial genome was sequenced manually by
standard direct-sequencing methodology, since low lev-
els of heteroplasmic banding were thought to be easier
to visualize by manual sequence. All family members
were screened for the presence of the mutation, by di-
rect sequencing of a PCR product spanning bases
12111–12467. Manual sequencing was performed by
standard methods, involving end-labeling of sequencing
primers with g[32P]-dATP (Amersham), and sequencing
using dideoxynucleotides and Sequenase (USB). The 270
normals used as controls were sequenced automatically
by an Applied Biosystems DNA sequencing kit and a
373A DNA sequencer (Applied Biosystems). Clones of
the MTTS2 gene obtained from PCRs of DNA from the
affected individuals discussed above were sequenced in
the same manner as were those from the controls.
Southern Blotting
Southern blotting using standard protocols was per-
formed on some family members, to ensure the absence
of mitochondrial deletions. A PCR fragment from
mtDNA was amplified (positions 9760–11399) by sin-
gle-stranded PCR in the presence of a[32P]-dCTP and
then was purified and used as a probe. The probe was
subsequently hybridized to total genomic DNA, cut with
PvuII, from individuals from family ZMK.
Cloning/Single-Strand Conformation–Polymorphism
Electrophoresis (SSCPE)
PCR products were amplified from muscle-biopsy
DNA from IV-22 and from blood-derived DNA from
IV-22, V-14, and IV-18, by use of forward and re-
verse primers that incorporated HindIII and XbaI sites,
respectively. The primers were as follows (primer tails
and enzyme sites are in parentheses): forward, (CT-
AGAAGCTT)CCGACATAATTACCGGGTTT; reverse,
(TTCATCTAGA)TTTGTTAGGGTTAACGAGGG;
aside from the primer regions shown in parentheses,
these oligonucleotides were identical to those used to
amplify control DNA for sequencing. PCR products
were cut with HindIII and XbaI and were cloned into
pcDNA3 (Invitrogen). Forty clones derived from each
individual were sequenced as one method of estimating
the percentage of heteroplasmy present in each DNA
sample. In addition, PCR fragments (positions
12111–12467) from all members of family ZMK were
used for SSCPE (Mansergh et al. 1998), and the wild-
type:mutant DNA ratios in different family members
were estimated.
Results and Discussion
Previous linkage studies resulted in exclusion of
90%–95% of the human nuclear genome, including
most previously reported loci for Usher syndrome, RP,
sensorineural deafness, and retinopathy (Kumar-Singh
et al. 1993a, 1993b; Kenna et al. 1997; and unpublished
results). A putative linkage was identified on the distal
end of chromosome 9q, as noted above. Later, however,
there were reasons to believe that the identification of
this candidate region on 9q was not secure. First, no
markers were found to be at zero recombination with
the disease locus, and all of the recombinant individuals
were affected. Second, D9S118 and D9S121 were ana-
lyzed by use of a subset of DNA samples from the CEPH
family, and the data were used to build a linkage map
of chromosome 9, which incorporated these markers
and some of those included in the Ge´ne´thon maps (fig.
2). The order of markers given by this map indicated
that the aforementioned markers were interspersed
closely with markers that had more recombinants with
Figure 2 Linkage map of microsatellite markers on chromosome 9. This map was created by CRI-MAP version 2.4 (Lander and Green
1987). Genotype data used to create this map were downloaded from the CEPH database and were merged with CEPH data from markers
D9S118 and D9S121 obtained by us. Approximate positions of nonuniquely placed markers are given on the right: markers indistinguishable,
by recombination, from just one other locus are placed beside the latter and are assumed to occupy roughly the same position; markers
indistinguishable, by recombination, from a number of uniquely placed loci are indicated beside the arrows. Each arrow defines the interval
between which the nonuniquely placed marker(s) beside and to the right of the pertinent arrow can be found. Male (McM), female (FcM) and
sex-averaged cM values for the genetic distances between the uniquely placed markers are given on the far left side of the diagram.
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the disease locus and that gave lower LOD scores. As a
result, multipoint analysis of the candidate region ex-
cluded it. Multipoint analysis was repeated by use of
only affected members of the pedigree, and again con-
vincing exclusions were obtained (fig. 3). Haplotype
analysis of this region revealed that no one common
haplotype was shared by all affected individuals (fig. 4).
Finally, recent diagnostic reassessment resulted in a ques-
tionable disease status for one unaffected member of the
pedigree. Unaffected individual III-5, although free of
symptoms in her 70s, has been found to have a grand-
daughter with symptoms of RP and hearing loss (R. Carr,
personal communication). Although individual III-5 was
omitted from all linkage analysis presented, this infor-
mation raises the possibility of reduced penetrance
within the family. Reduced penetrance had not been con-
sidered previously, since the majority of family members
assessed were affected and no prior evidence for skipped
generations had been noted.
Cytoplasmic inheritance had previously been consid-
ered as a possibility in this pedigree but was considered
less likely than nuclear inheritance, since information
from older family members indicated that individual
I-2 had no visual or hearing difficulties well into her 80s,
which suggested the possibility that her spouse had
transmitted the disease locus in this family. Such an in-
stance of male-to-offspring transmission would rule out
mitochondrial inheritance of the disease. However, there
is limited information concerning I-1, who died around
the turn of the century. Given our recent findings, it is
likely that his wife, I-2, may possibly have been an
asymptomatic carrier of a germ-line mitochondrial
mutation.
Some observations of family ZMK were suggestive of
a mitochondrial disorder. There is no male-to-offspring
transmission in the pedigree, although, given that few
of the affected males have married, this may be merely
coincidental. Affected individuals, in addition to having
hearing loss, complained of marked recruitment (dis-
tortion and physical discomfort as a result of loud noise)
and persistent tinnitus (Kenna et al. 1997). Similar symp-
toms have been noted in persons with hearing loss
caused by known mitochondrial mutations (W. J. Kim-
berling, personal communication). Four affected indi-
viduals (IV-22, V-4, V-5, and V-6) were assessed by elec-
trocardiography. All were found to have right-axis
deviation, and one individual showed signs of global
hypertrophy. Individual IV-22 also underwent electro-
myography and a muscle biopsy. Results showed elec-
tromyographic abnormalities and an excessive number
of mitochondria within muscle tissue (Kenna et al.
1997). Such cardiac and muscular abnormalities could
be consistent with the presence of a mitochondrial dis-
order, since respiratory dysfunction in postmitotic tissues
such as cardiac and skeletal muscle can result in exces-
sive mitochondrial proliferation and conduction defects
(Zeviani et al. 1989; diMauro and Hirano 1998). In
addition to the subclinical symptoms noted above, sen-
sorineural hearing loss and pigmentary retinopathy are
disorders that have been known to result frommutations
within the mitochondrial genome (Zeviani et al. 1989).
The aforementioned incidence of reduced penetrance
within a pedigree that is otherwise composed largely of
affected individuals was also suggestive. Therefore, after
excluding most of the nuclear genome, we screened for
mutations in the mitochondrial genome of this kindred.
The complete mitochondrial sequence was obtained
for four family members, including two severely affected
individuals, one mildly affected individual, and an un-
affected control. The DNA from one of the severely af-
fected individuals was obtained from a muscle-biopsy
sample; the other DNA samples were purified from pel-
leted blood lymphocytes. A number of variations from
the consensus sequence were noted (table 1), most of
which were polymorphic variants that have been re-
ported elsewhere (MITOMAP, v3.0). Four previously
unrecorded sequence changes were noted. Two of these
were within amino acid–encoding regions of the mito-
chondrial genome and were found to be silent substi-
tutions. The third sequence variant was heteroplasmic
and was found within the gene encoding MTTS2 (fig.
5). Noteworthy is that it was found only in family mem-
bers and was not present in 270 normal individuals
from the same ethnic background as family ZMK. Fur-
ther evidence for the pathogenicity of the C12258A se-
quence variant was obtained from sequence analysis. A
sequence alignment of MTTS2 genes from various spe-
cies—including those as evolutionarily divergent from
Homo sapiens as vulture, platypus, and frog—shows
that the C at position 12258 is highly conserved (table
2). Therefore, this study provides substantive evidence
that the 12258 mtDNA mutation is the cause of the
symptoms observed in family ZMK.
Varying degrees of heteroplasmy between family
members were also assessed, since levels of heteroplasmy
can be correlated with severity of symptoms in mito-
chondrial disorders (Zeviani et al. 1989; diMauro and
Hirano 1998). Given that both muscle- and blood-de-
rived DNA samples from individual IV-22 were avail-
able, differences in heteroplasmy between muscle- and
blood-derived DNA samples were also noted. Levels of
heteroplasmy were assessed by various methodologies.
The complete family was sequenced, and differences in
relative band intensity were estimated by eye. In addi-
tion, an SSCPE analysis of affected family members was
undertaken, and relative band intensities were evaluated
(fig. 6). Muscle- and blood-derived DNAs from individ-
ual IV-22 were amplified by PCR separately and were
cloned into pcDNA3. Forty individual clones from each
DNA type were sequenced to estimate the proportion of
Figure 3 Multipoint analysis of only the affected members of the pedigree, indicating that the disease gene in family ZMK is significantly excluded from the 9q region where there previously
had been a suggestion of linkage. Markers that map exactly to the same position are immediately adjacent to one another and underlined.
Figure 4 Haplotypes on 9q in family ZMK. Note the transmission of different chromosome types through the pedigree; those shared by related individuals are depicted as shaded bars. No one
haplotype is shared by all affected individuals. In addition, the two separate branches of the family do not appear to have in common any 9q portion between HXB and the telomere. The region of
tightest linkage is between markers D9S260 and D9S121 inclusive. There are four recombinants with the disease locus in this region—namely, those in IV-16, IV-34, and V-14 and that between the
two major branches of the family. Individuals IV-16, IV-34, and V-14 are consistently recombinant with the disease locus, right across the region examined. Two of these individuals have affected
offspring, and V-14 is severely affected; he was legally blind at age 21 years. In addition, individual III-5 has an affected granddaughter, increasing to five the number of recombinants with the disease
locus. The most likely explanation for these data is that the disease locus is not on 9q.
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Table 1
Sequence Variations in Family ZMK
POSITION
BASE IN
GENE
AMINO
ACID
Consensus
Sequence
Family
ZMK
533 A G Control )
6776 T C MTCO1 H-H
11953 C T MTND4 L-L
12258 C A MTTS2 )
13404 T C MTND5 I-I
14272 C G MTND6 F-L
14569 G A MTND6 P-P
14766 A G MYCYB I-T
16239 C G Control )
16519 T C Control )
16569 T C Control )
NOTE.—The putative disease-causing mutation in the serine tRNA
gene is boxed. Additional sequence variations were found both in
“married-in” members of family ZMK and across all four individuals
sequenced, including the unaffected control individual (data not pre-
sented). Many of the variations from the consensus sequence presented
above are either previously reported sequence variations (underlined)
or do not alter encoded amino acids.
Figure 5 Sequence analysis of mtDNA samples from blood lym-
phocytes (A) and muscle (B) from affected individual IV-22 and from
blood lymphocytes from an unaffected control (C). The CrAmutation
at position 12258 (r) is present in both affected individuals and is
absent in the unaffected control.
mutant mtDNA present in each tissue. Similarly, blood-
derived DNAs from individuals IV-18 (asymptomatic)
and V-14 (severely affected) were cloned, and 40 clones
per individual were sequenced (table 3).
It is noteworthy that sequence, SSCPE, and cloning
data demonstrated a large variance in the proportion of
mutant mtDNAs in muscle and blood derived from the
same individual. Quadriceps femoris–derived skeletal
muscle from individual IV-22 appeared to contain
∼85%–95% mutant mtDNAs, whereas blood appeared
to contain near-equal proportions of mutant and normal
mtDNAs (table 2). It is therefore possible that there may
also be high proportions of mutant mtDNAs in the ret-
inas and cochleas of affected individuals, thus giving rise
to the symptoms observed. This may be the case in af-
fected family members, since it is known that, for some
mitochondrial mutations, a low proportion of wild-type
mtDNA can be sufficient to protect the cell from the
deleterious effects of a pathogenic mtDNA mutation.
For example, it has been shown in variousmitochondrial
disorders that respiratory function is severely compro-
mised only when the proportion of mutated mtDNAs
increases to 180%–90% (Zeviani et al. 1989; Chomyn
1998; Schapira 1998).
The mutated A band (fig. 5) was detectable in se-
quences from all family members, with the exception of
individuals III-3 and III-5. Individual III-3 was assessed
as unaffected in her 80s and may be free of the mutation.
Her affection status is therefore slightly questionable. In
contrast, individual III-5, although diagnosed as unaf-
fected herself (in her mid 70s), has a granddaughter
(V-1, who is in her 20s) with advanced RP and hearing
loss. One possibility may be that individual III-5 inher-
ited a low proportion of mutant mtDNA. Cells carrying
a high load of mutated mtDNA molecules may be se-
lected against in rapidly dividing tissues, as a result of
their comparatively inefficient energymetabolism (Shoff-
ner andWallace 1992; Chomyn 1998; diMauro andHir-
ano 1998; Siregar et al. 1998). Over a lifetime, this can
result in a significant reduction in the proportion of ab-
normal mtDNAs in dividing tissues such as hematopoi-
etic stem cells, thus rendering detection of the mutant
mtDNA species more difficult in blood-derived DNA of
patients. Although the mutation in individual III-5 is
absent in blood, this individual may have carried suffi-
cient levels of the C12258A mutation in germ-line
mtDNAs to pass it on to her descendants. There is in
mammalian oogenesis a well-documented bottleneck ef-
fect that can result in a mother, who herself has a low
proportion of a heteroplasmic mtDNA variant, passing
on that variant, to her offspring, at high concentrations
(Grossman 1990; Shoffner and Wallace 1992; Poulton
et al. 1998).
Individuals V-1, V-3, III-18, IV-20, V-16, V-10, and
V-12, who were diagnosed as unaffected, show the
C12258A band after sequence analysis. Some of these
individuals are young and, given the variability, in both
age at onset and severity, observed within the family,
may yet develop symptoms. Alternatively, there may be
a threshold below which lower levels of the mutant do
little damage. Marked variability in the severity of symp-
toms observed for small variations in relative levels
of mutant mtDNAs has been noted in other mitochon-
drial disorders, including mitochondrial encephalomy-
opathy/lactic acidosis/strokelike episodes (MELAS
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Figure 6 SSCPE analysis using PCR-amplified DNA from mem-
bers of family ZMK. It is noteworthy that the wild-type (upper band)
and mutant (lower band) mtDNA fragments can be distinguished.Both
conformations of mtDNA are present in most affected individuals (e.g.,
see lanes 2, 5, and 8–10). However, some affected individuals have
mtDNA that is mostly mutant. It is noteworthy that the wild-type:
mutant mtDNA ratio in blood and muscle tissue varies significantly
in individual IV-22 (lanes 2 and 3). The data indicate that there is no
clearly evident correlation between the wild-type:mutant mtDNA ratio
in blood and disease severity.
Table 2
CLUSTAL W(1.7) Multiple Sequence Alignment of MTTS2 in Various Species
Source/Species Sequencea
* ******* * ** * * *
MTTS2 (mutation)b GAGAAAGCTCA––––CAAGAACTGC–T–AACT–CATGCCCCCATGTCTAAC–AA–CATGGATTT–CTC
Human GAGAAAGCTCA––––CAAGAACTGC–T–AACT–CATGCCCCCATGTCTAAC–AA–CATGGCTTT–CTC
Chimpanzee GAGAAAGCTTA––––TAAGAACTGC–T–AATT–CATATCCCCATGCCTAAC–AA–CATGGCTTT–CTC
Gibbon GAGAAAGCCCA––––CAAGAACTGC–T–AACT–CACTATCCCATGTATAAC–AA–CATGGCTTT–CTC
Mouse AAGAAAGATTG––––CAAGAACTGC–T–AATT–CATGCTTCCATGTTTAAA–AA–CATGGCTTT–CTT
Rhinoceros GAGAAAGCACT––––CAAGAACTGC–T–AACT–CATGCCCCCATATTTAAC–AA–TATGGCTTT–CTC
Cat GAAAAAGTATG––––CAAGAACTGC–T–AATT–CATGCCTCCACGTATAAA–AA–CGTGGCTTT–TTC
Seal GAAAAAGAATG––––CAAGAACTGC–T–AACT–CATGCCCCCACGTATAAA–AA–CGTGGCTTT–TTC
Horse GAGAAAGTATG––––CAAGAACTGC–T–AATT–CATGCCCCCATGTCCAAC–AAACATGGCTCT–CTC
Donkey GAGAA–GTATG––––CAAGAACTGCCT–AATT–CATGCTTCCGCGTCTGAC–AAACACGGCTCT–CTC
Opossum GAGAATGCA–T––––CAAGAACTGC–T–AATT–CATGAACCCATATTTAAC–AA–TATGGCTTT–CTC
Platypus GAGAGAGAA–A––––TAAGAACTGC–T–AATC–CTTAACTTCATGCCTAAC–CA–CATGACTCTACTT
Vulture GTTACAACCAG––––CAGGAACTGC–T–AACT–CTTGCATCTGAGTCTAAA–AC–CTCAGCCC–CCTT
Frog GAACTTGACTGGACCTAAGAACTGC–T–AATTACTTACG–CTGTG–TTCATTC––CACGGCTTG–TTC
a An asterisk (*) denotes a position that is conserved in all species listed as well as in MTTS2 in family ZMK. Note
the conservation, at position 12258 (underlined), of the normal C base in all species included in the alignment;
Drosophila, Saccharomyces crevisiae, and Asterinia pectinifera sequences were also examined but showed no consensus
in the sequence.
b Variant found in family ZMK.
[MIM 54000]), myoclonic epilepsy with ragged red fi-
bers (MERRF [MIM 54500]), and neuropathy/ataxia/
retinitis pigmentosa (NARP [MIM 551500]) (Zeviani et
al. 1989; Chomyn 1998; Schapira 1998). Finally, the
relative proportions of mutated mtDNAs in different tis-
sues may vary widely, both as a result of random genetic
drift during development and as a result of selection
during aging, as mentioned above (diMauro and Hirano
1998). Levels of a heteroplasmic variant in blood are
therefore not a reliable indicator of its frequency in other
tissues.
It is noteworthy that a number of syndromes with
symptoms overlapping, in part, with those seen in fam-
ily ZMK have involved large mitochondrial deletions.
For example, Kearns-Sayre syndrome (MIM 530000),
which is caused by deletions in mtDNA, can include
RP, progressive external ophthalmoplegia, and progres-
sive hearing loss among its symptoms (Wallace et al.
1995; Kogelnik et al. 1996), and a familial syndrome
incorporating sensorineural deafness and non–insulin-
dependent diabetes (MIM 520000) has been linked to
a 10.4-kb mitochondrial deletion (Ballinger et al. 1992).
Although none of the affected members of family ZMK
have diabetes or show the external ocular mus-
cle–movement disorders characteristic of Kearns-Sayre
syndrome (Kenna et al. 1997), a Southern blot was un-
dertaken to address the possibility that a large-scale mi-
tochondrial deletion is the cause of disease in family
ZMK. It is noteworthy that only the expected linearized
mtDNA fragment of 16.5 kb was observed, reducing the
likelihood of a mitochondrial deletion segregating
through family ZMK. Typically, disorders caused by
large-scale mtDNA deletions, duplications, and re-
arrangements are usually sporadic and often result in
premature fatality (Zeviani et al. 1990). There is no ev-
idence to suggest that, as a result of their disorder, af-
fected members of family ZMK suffer significant reduc-
tions in life span.
Given that this study provides substantive evidence
that a mitochondrial mutation, C12258A in the gene
encoding MTTS2, is the cause of progressive sensori-
neural deafness and RP in family ZMK, it is of interest
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Table 3
Heteroplasmy Estimated by Sequencing and by Cloning
Heteroplasmy-Estimation
and Individual A:C Ratioa Tissue Statusb
Sequencing:c
III-3 0:100 Blood Asymptomatic
III-5 0:100 Blood Asymptomatic
III-9 5:95 Blood Unclear
IV-14 50:50 Blood Affected
IV-15 30:70 Blood Affected
IV-16 40:60 Blood Affected
IV-17 0:100 Blood Married-in
V-1 80:20 Blood Asymptomatic
V-2 95:5 Blood Affected
V-3 40:60 Blood Asymptomatic
IV-18 60:40 Blood Asymptomatic
IV-20 40:60 Blood Asymptomatic
IV-22 50:50 Blood Affected
IV-22 95:5 Muscle Affected
IV-23 0:100 Blood Married-in
V-4 80:20 Blood Affected
V-5 80:20 Blood Affected
V-6 80:20 Blood Affected
IV-24 50:50 Blood Affected
IV-27 30:70 Blood Affected
IV-28 50:50 Blood Affected
IV-32 10:90 Blood Affected
IV-33 0:100 Blood Married-in
V-16 20:80 Blood Asymptomatic
IV-34 50:50 Blood Affected
IV-35 0:100 Blood Married-in
V-17 80:20 Blood Affected
IV-38 40:60 Blood Affected
IV-39 0:100 Blood Married-in
V-8 50:50 Blood Affected
V-10 40:60 Blood Asymptomatic
V-12 40:60 Blood Asymptomatic
V-14 60:40 Blood Affected
IV-40 20:80 Blood Affected
IV-41 50:50 Blood Affected
Cloning:
IV-22 37:3 Muscle Affected
IV-22 25:15 Blood Affected
V-14 24:16 Blood Affected
IV-18 16:24 Blood Asymptomatic
a A  mutated variant; C  normal base.
b “Asymptomatic” has been used to denote unaffected individuals,
since some of them are still young and there is evidence for a widely
variable age at onset and penetrance in the pedigree. Similar results
were obtained with SSCPE analysis (see fig. 6).
c Heteroplasmy estimated by eye.
to speculate as to possible mechanisms by which this
mutation has a deleterious effect. A cursory review of
tRNA structure indicates that the C12258A mutation is
situated within the amino acid–acceptor arm of the mol-
ecule. The presence of the mutant A at this position
would be expected to disrupt base pairing of the acceptor
arm, resulting in a change or destabilization of the tRNA
secondary structure. Such a change in the tRNA sec-
ondary structure could result in inefficient aminoacyla-
tion of the tRNA. Alternatively, the variant tRNAs may
be degraded more rapidly. Either or both mechanisms
would probably result in a reduction in the pool of
charged serine (i.e., AGY) tRNAs available for trans-
lation. An increase in the uncharged:charged tRNA ratio
may lead to incorporation of uncharged tRNAs into the
ribosomal active site, resulting in premature termination
of transcripts. Prior studies of the MERRF 8344 tRNA
Lys mutation (MIM 590060.0001) show precedents for
both mechanisms. In this condition, levels of the tRNA
have been thought to decline by 18%–35% while charg-
ing of the variant tRNA with lysine is reduced by
30%–40%. Prematurely terminated transcripts have
also been observed (Chomyn 1998). Another possibility
is that the mutation could interfere in some way with
processing of the polycistronic mRNA produced from
transcription of the mitochondrial heavy strand. The
previously described 7445 tRNA Ser (UCN) deafness
(MIM 590080) mutation is thought to act in this way,
at least in part (Fischel-Ghodsian 1998a, 1998b).
Regardless of the precise mechanism, if the pool of
charged serine tRNAs is reduced, one would expect a
resulting reduction in the efficiency of mitochondrial
translation, which would impair mitochondrial ATP
production, thereby reducing the energy available to the
cell. Neural tissues (including retina and cochlear hair
cells), have the highest energy demands of any tissue in
the body, followed by muscle tissue (Zeviani et al. 1993;
Fischel-Ghodsian 1998a, 1998b; Schapira et al. 1998).
This provides a coherent reason why symptoms involv-
ing various progressive visual, auditory, muscular, car-
diac, and neuropathic abnormalities almost always ac-
company mitochondrial disorders. Another factor that
increases the vulnerability of neural and muscular tissues
to mitochondrial disorders is that cells containing high
loads of dysfunctional mitochondria are less efficiently
selected against in nondividing cells, leading to the pres-
ence of a higher proportion of such cells in these tissues.
Compromised respiratory function has a number of
deleterious effects on cells. It is known to result in the
excessive generation of free radicals (Zeviani et al. 1989;
Schapira 1998), which are mutagenic to any remaining
wild-type mtDNAs. A further increase in the number of
mutant mtDNAs can only impair the respiratory pro-
cesses further, thus amplifying the problem. Impaired
oxidative phosphorylation may lead to decreases in mi-
tochondrial transmembrane potential. Such decreases
are known to play an early part in apoptosis, or pro-
grammed cell death (Schapira 1998). In this regard, it
is of interest that some photoreceptor degenerationshave
been shown to involve apoptotic mechanisms (Travis
1998). Hence, one possible future approach to therapy
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may be to modulate key proteins involved in the apop-
totic pathway (Hafezi et al. 1997).
There are a number of possibilities as to why the retina
and cochlea in family ZMK are more vulnerable to the
deleterious effects of the 12258 mutation than are other
neural or muscle tissues. First, these tissues may have
energy demands that are exceptionally high even in com-
parison with those of other neurons. Photoreceptors are
thought to be exceptionally sensitive to reductions in
respiratory capacity (Travis 1998). In addition, mild mi-
tochondrial mutations that can appear in homoplasmic
form, such as those causing Leber hereditary optic neu-
ropathy (LHON [MIM 535000]) and deafness, cause
ocular or auditory symptoms, typically without involv-
ing other tissue types. Further support for this hypothesis
is provided by the observation that two of the most
severely affected family members are also mentally sub-
normal, suggesting the possible involvement of other
neural tissues as the mutation load increases. Other ex-
planations have been put forward for the observed tis-
sue-specific effects of various mitochondrial mutations.
Mitochondrial gene products may have tissue-specific
functions unrelated to their mitochondrial function. Al-
ternatively, gene products that help to regulate mito-
chondrial function may vary in a tissue-specific manner,
rendering some tissues more sensitive to particular mu-
tations (Fischel-Ghodsian 1998a, 1998b). Varying levels
of mutant mtDNAs between individuals could explain
the differences in both severity and age at onset that
have been observed in family ZMK. Another explana-
tion for variations in severity and age at onset would be
interindividual differences in the nuclear-DNA back-
ground. However, linkage studies thus far have shown
little evidence for susceptibility loci of large effect. Mul-
tipoint analyses in the area of the putative disease locus
on chromosome 9 resulted in convincing exclusion of
the region. Moreover, two-point linkage analyses have
been undertaken that have used affected members only
and the 400-plus markers that have been typed through
the family. It is noteworthy that no significant areas of
linkage were established (data not shown).
Although there are no precedents for the precise com-
bination of symptoms observed in this family, there are
many examples of mitochondrial disorders that mani-
fest either progressive hearing loss or a retinopathy. RP
or similar retinal degenerations are a feature of NARP
(MIM 551500) (Holt et al. 1990) and Kearns-Sayre syn-
drome (MIM 530000) and are sometimes associated
with the MELAS (MIM 54000) 3243 mutation (Sue
et al. 1997). Mutations at positions 1555 (MIM
561000.0001) and 7445 (MIM 590080.0002) have been
shown to cause both aminoglycoside-induced or spon-
taneous hearing loss (Prezant et al. 1993, Reid et al.
1994), whereas other mtDNA anomalies can result in
hearing loss associated with diabetes or with ataxia and
myoclonus (Ballinger et al. 1992; van den Ouweland et
al. 1992; Tiranti et al. 1995). Cardiac and musculo-
skeletal abnormalities are also associated with a large
number of mitochondrial disorders (Zeviani et al. 1989)
and usually manifest much more severely than they do
in family ZMK.
The results from this study have significant implica-
tions for the etiologies of various retinopathies and
forms of hearing loss, especially the various forms of
Usher syndrome. To date, eight loci for Usher syndrome
have been mapped to the nuclear genome; two of these
genes, those causing USH1B and USH2A, have been
identified (Weil et al. 1995; Eudy et al. 1998). Addi-
tionally, families with some Usher syndrome do not
show linkage to any previously mapped loci, suggesting
further genetic heterogeneity. It is possible that some
unmapped families with Usher syndrome may carry the
C12258A mutation. Seemingly dominant or partially
dominant inheritance of Usher III has been noted in some
patients (W. J. Kimberling, personal communication).
Hence, an extensive screening for mitochondrial muta-
tions in patients with Usher syndrome should be un-
dertaken. Such a study may subsequently be extended
to patients suffering from disorders involving visual or
hearing loss alone. The observation that a mitochondrial
mutation causes a disease akin to Usher syndrome raises
the previously unconsidered possibility that the mapped
but unidentified genes causing some forms of Usher syn-
drome may be involved in mitochondrial metabolism.
Such a situation would not be without precedent; syn-
dromes resembling those caused by mitochondrial mu-
tations have been mapped to the nuclear genome; these
include mtDNA deletion syndromes inherited in an au-
tosomal dominant fashion ([MIM 550000] Zeviani et
al. 1989, 1990; [MIM 601226] Kaukonen et al. 1996),
a form of Leigh syndrome ([MIM 256000] Bourgeron
et al. 1995), and Friedreich ataxia ([MIM 229300]
Schapira 1998), some cases of which are known to be
caused by mutations in genes involved in mitochondrial
metabolism. The mammalian mitochondrial genome en-
codes only 13 of the 50 proteins that constitute res-
piratory complexes and encodes none of the proteins
involved in mitochondrial replication, transcription, and
translation. To date, few of the nuclear genes that play
a role in healthy mitochondrial function have been
cloned. The involvement of such genes in the etiology
of diverse genetic degenerative disorders may have been
underestimated thus far. We would therefore hope that
discovery of the C12258A mutation will aid in both the
further understanding of the molecular pathogenesis of
Usher syndrome and our knowledge of mitochondrial
disorders in general. Undoubtedly, such knowledge will
aid in the future development of therapies for this group
of debilitating disorders.
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